Corbus Pharmaceuticals Holdings, Inc. (CRBP)
- Previous Close
43.74 - Open
43.65 - Bid 42.52 x 100
- Ask 43.06 x 200
- Day's Range
40.51 - 43.88 - 52 Week Range
3.03 - 49.87 - Volume
92,145 - Avg. Volume
288,904 - Market Cap (intraday)
451.705M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-10.31 - Earnings Date Aug 6, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
68.00
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
www.corbuspharma.comRecent News: CRBP
Performance Overview: CRBP
Trailing total returns as of 5/10/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CRBP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CRBP
Valuation Measures
Market Cap
451.71M
Enterprise Value
451.68M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.49k
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.36%
Return on Equity (ttm)
-59.52%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-33.76M
Diluted EPS (ttm)
-10.31
Balance Sheet and Cash Flow
Total Cash (mrq)
120.1M
Total Debt/Equity (mrq)
17.83%
Levered Free Cash Flow (ttm)
--
Research Analysis: CRBP
Company Insights: CRBP
CRBP does not have Company Insights